JP2021519089A5 - - Google Patents

Info

Publication number
JP2021519089A5
JP2021519089A5 JP2020551924A JP2020551924A JP2021519089A5 JP 2021519089 A5 JP2021519089 A5 JP 2021519089A5 JP 2020551924 A JP2020551924 A JP 2020551924A JP 2020551924 A JP2020551924 A JP 2020551924A JP 2021519089 A5 JP2021519089 A5 JP 2021519089A5
Authority
JP
Japan
Prior art keywords
chimeric protein
protein complex
complex according
based chimeric
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519089A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024714 external-priority patent/WO2019191519A1/en
Publication of JP2021519089A publication Critical patent/JP2021519089A/ja
Publication of JP2021519089A5 publication Critical patent/JP2021519089A5/ja
Priority to JP2024006808A priority Critical patent/JP2024028543A/ja
Pending legal-status Critical Current

Links

JP2020551924A 2018-03-28 2019-03-28 二官能性タンパク質およびその作製 Pending JP2021519089A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024006808A JP2024028543A (ja) 2018-03-28 2024-01-19 二官能性タンパク質およびその作製

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862649248P 2018-03-28 2018-03-28
US201862649238P 2018-03-28 2018-03-28
US201862649264P 2018-03-28 2018-03-28
US62/649,264 2018-03-28
US62/649,238 2018-03-28
US62/649,248 2018-03-28
PCT/US2019/024714 WO2019191519A1 (en) 2018-03-28 2019-03-28 Bi-functional proteins and construction thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024006808A Division JP2024028543A (ja) 2018-03-28 2024-01-19 二官能性タンパク質およびその作製

Publications (2)

Publication Number Publication Date
JP2021519089A JP2021519089A (ja) 2021-08-10
JP2021519089A5 true JP2021519089A5 (cg-RX-API-DMAC7.html) 2022-04-05

Family

ID=68060793

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551924A Pending JP2021519089A (ja) 2018-03-28 2019-03-28 二官能性タンパク質およびその作製
JP2024006808A Pending JP2024028543A (ja) 2018-03-28 2024-01-19 二官能性タンパク質およびその作製

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024006808A Pending JP2024028543A (ja) 2018-03-28 2024-01-19 二官能性タンパク質およびその作製

Country Status (8)

Country Link
US (1) US20210024631A1 (cg-RX-API-DMAC7.html)
EP (1) EP3773674A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021519089A (cg-RX-API-DMAC7.html)
KR (2) KR20260100427A (cg-RX-API-DMAC7.html)
CN (1) CN112512551A (cg-RX-API-DMAC7.html)
AU (2) AU2019243580A1 (cg-RX-API-DMAC7.html)
CA (1) CA3095310A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019191519A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3455245A2 (en) * 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
KR102642385B1 (ko) * 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
CN117924493A (zh) * 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
CA3090406A1 (en) * 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
EP3890773A4 (en) * 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
CN113840833B (zh) * 2019-03-28 2025-06-17 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ,インコーポレイテッド 治療用インターフェロンアルファ1タンパク質
JP7729778B2 (ja) * 2019-03-28 2025-08-26 オリオニス バイオサイエンシズ,インコーポレイテッド Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Il13を含む融合タンパク質
JPWO2020250706A1 (cg-RX-API-DMAC7.html) 2019-06-12 2020-12-17
US11636771B2 (en) 2019-09-08 2023-04-25 Deere & Company Stackable housing containers and related systems
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2021144415A1 (en) * 2020-01-17 2021-07-22 Universiteit Gent Immunoglobulin single domain antibodies for delivery of mucosal vaccines
JP7512413B2 (ja) * 2020-03-31 2024-07-08 ビオテウス・インコーポレイテッド 抗pd-l1およびpd-l2抗体ならびにその誘導体および用途
WO2021230460A1 (ko) * 2020-05-14 2021-11-18 주식회사 제넥신 Pd-l1 단백질 및 단량체성 il-10 변이체가 포함된 융합 단백질 및 이의 용도
CA3185087A1 (en) * 2020-07-07 2022-01-13 Nikolai Kley Immunostimulatory adjuvants
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer
WO2022089418A1 (zh) * 2020-10-26 2022-05-05 信达生物制药(苏州)有限公司 重组截短FLT3配体与人抗体Fc的融合蛋白
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
WO2022133094A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Fap binding molecules and uses thereof
WO2022221746A1 (en) * 2021-04-16 2022-10-20 Orionis Biosciences, Inc. Il-2 based constructs
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
TW202309102A (zh) * 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
WO2023016564A1 (zh) * 2021-08-12 2023-02-16 上海才致药成生物科技有限公司 靶向GPC3的抗体干扰素α融合蛋白及其用途
TW202319397A (zh) * 2021-08-30 2023-05-16 美商英伊布里克斯公司 NKp46結合多肽及其用途
TW202328171A (zh) * 2021-08-30 2023-07-16 美商英伊布里克斯公司 靶向NKp46之經修飾之IL-2多肽及其用途
CN118317785A (zh) * 2021-09-13 2024-07-09 根特大学 氨肽酶n特异性单克隆抗体及其用途
US20240400633A1 (en) * 2021-09-30 2024-12-05 Orionis Biosciences, Inc. Split human ifn-gamma and tnf-alpha constructs and uses thereof
US12559576B2 (en) * 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
CN119403568A (zh) * 2022-04-07 2025-02-07 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
WO2023201051A2 (en) * 2022-04-15 2023-10-19 Palleon Pharmaceuticals Inc. Anti-inflammatory siglec-6 proteins and methods of making and using same
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
CN116286844A (zh) * 2023-02-13 2023-06-23 浙江大学 人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途
CN116144668A (zh) * 2023-02-13 2023-05-23 杭州吉倍思生物制药有限公司 人il-1r1基因、蛋白、同源二聚体蛋白质与用途
IL327059A (en) * 2023-09-11 2026-05-01 Shanghai Btd Bio Tech Co Ltd A long-acting fusion protein that is an agonist for the parathyroid hormone receptor, and its use
CN122422358A (zh) * 2023-11-17 2026-07-17 奥里尼斯生物科学有限公司 基于pd-l1的嵌合蛋白制剂
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327199D1 (de) * 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
EP2343081A1 (en) * 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
EP4169525A1 (en) * 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
PL2822575T3 (pl) * 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
WO2014198748A1 (en) * 2013-06-11 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
PE20170908A1 (es) * 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3371311B1 (en) * 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US11370826B2 (en) * 2016-02-09 2022-06-28 Bracco Suisse Sa Recombinant chimeric protein for selectins targeting
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof

Similar Documents

Publication Publication Date Title
AU2022218544B2 (en) Hetero-dimeric multi-specific antibody format
Sedykh et al. Bispecific antibodies: design, therapy, perspectives
Kontermann Dual targeting strategies with bispecific antibodies
EP3443006B1 (en) Trispecific and/or trivalent binding proteins
Nuñez-Prado et al. The coming of age of engineered multivalent antibodies
JP2023123649A5 (cg-RX-API-DMAC7.html)
JP2021118723A5 (cg-RX-API-DMAC7.html)
JP7486810B2 (ja) IgG1 Fcモノマー、及びその使用
JP2022511135A (ja) アルブミン結合ドメイン融合タンパク質
JP2020036595A5 (cg-RX-API-DMAC7.html)
JP2024521405A5 (cg-RX-API-DMAC7.html)
JPWO2002033073A1 (ja) 低分子化アゴニスト抗体
CA2411374A1 (en) Dual specificity antibodies and methods of making and using
JP2023526282A5 (cg-RX-API-DMAC7.html)
JP2022544785A5 (cg-RX-API-DMAC7.html)
US20230272110A1 (en) Antibodies that bind psma and gamma-delta t cell receptors
JP2025508882A5 (cg-RX-API-DMAC7.html)
US20200181263A1 (en) Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
CN116284396B (zh) NKp46抗体及其用途
IL300062A (en) Dual fused cytokine proteins containing IL-10
Rossi et al. Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2–bispecific antibody is enhanced in combination with interferon-α
US20110165122A1 (en) Method for targeted and sustained antiviral therapy
JP2022550345A5 (cg-RX-API-DMAC7.html)
WO2001079494A1 (fr) Anticorps agonistes
RS64771B1 (sr) Trispecifični i/ili trovalentni vezujući proteini